Our Molecular Genetics portfolio provides solutions for all areas of disease, including screening, diagnosis, and monitoring. Through a range of partners, Abacus dx aims to provide Australian and New Zealand laboratories with simple and efficient testing solutions for a range of methods including polymerase chain reaction, next-generation sequencing, and fluorescence in situ hybridisation.
ESR1 Mutations are the Leading Cause of Primary Treatment Resistance in HR+ mBC
ESR1 gene codes for estrogen receptor alpha (ERα), and mutations in its ligand-binding domain trigger constant activation of the receptor, leading to excessive downstream signalling.
The Idylla™ POLE-POLD1 Mutation Assay (RUO)* provides a rapid and reliable solution to close an important gap in oncology research by enabling molecular classification of endometrial cancer samples. Its fully automated solution is capable to detect 99% of […]
Idylla™ ThyroidPrint® Assay (RUO)* is a novel RT qPCR-based molecular signature that assesses a gene expression profile. Using a proprietary algorithm, ThyroidPrint provides assessment of indeterminate thyroid nodule cytology, classifying as low or high risk of malignancy.
[…]
Biocartis Idylla™ for colorectal cancer
The Idylla solution is a revolutionary, fully automated, real-time PCR based molecular testing system designed to offer results in a minimum amount of time.
[…]
Introducing the Asuragen AmplideX® Nanopore Carrier Plus Kit* – a revolutionary solution for carrier screening for challenging hard-to-read genes, leveraging long-read sequencing technology to provide unparalleled insights into genetic conditions. Expanded prenatal screening protocols traditionally require multiple methods to […]
Discover the Invivoscribe control portfolio
Invivoscribe offers an extensive range of General Purpose Reagents (GPRs) and Research Use Only (RUO) controls.
[…]